The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel.

Saved in:
Bibliographic Details
Title: The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel.
Authors: Chistiakov DA; Department of Molecular Diagnostics, National Research Center GosNIIgenetika, Moscow, Russia. dimitry.chistiakov@lycos.com, Potapov VA, Smetanina SA, Bel'chikova LN, Suplotova LA, Nosikov VV
Source: Acta diabetologica [Acta Diabetol] 2011 Sep; Vol. 48 (3), pp. 227-35. Date of Electronic Publication: 2011 May 25.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-5233
DOI:10.1007/s00592-011-0299-4